Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.

BACKGROUND The functional roles of deoxycytidine kinase (dCK) in acquired resistance to gemcitabine remain unknown in pancreatic cancer. Here, the functional involvement of dCK in gemcitabine-resistance of pancreatic cancer was investigated. MATERIALS AND METHODS The levels of the dCK gene as well as other gemcitabine-related genes (hENT1, RRM1 and RRM2) were analyzed in gemcitabine-resistant pancreatic cancer cells (GR cells) using quantitative real-time reverse transcription polymerase chain reaction. The effects of inhibition of these genes on sensitivity to gemcitabine were evaluated. RESULTS In GR cells, expression of dCK was significantly reduced compared with that of parental cells (p < 0.05). The dCK-targeting siRNA significantly reduced gemcitabine sensitivity (p < 0.01) without affecting cell proliferation. The RRM1- and RRM2-targeting siRNAs increased gemcitabine sensitivity (p < 0.05) and reduced cell proliferation even without gemcitabine treatment. The hENT-targeting siRNA did not affect gemcitabine sensitivity or cell proliferation. CONCLUSION Down-regulation of dCK specifically enhanced acquired resistance to gemcitabine in pancreatic cancer cells without affecting their proliferation.

[1]  C. Iacobuzio-Donahue,et al.  Immunohistochemical and Genetic Evaluation of Deoxycytidine Kinase in Pancreatic Cancer: Relationship to Molecular Mechanisms of Gemcitabine Resistance and Survival , 2006, Clinical Cancer Research.

[2]  J. Mackey,et al.  Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene , 2004, BMC pharmacology.

[3]  T. Okumura,et al.  Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells , 2007, British Journal of Cancer.

[4]  V. Heinemann,et al.  Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. , 1988, Cancer research.

[5]  John R. Mackey,et al.  The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma , 2004, Clinical Cancer Research.

[6]  J. Tepper,et al.  Tumor uptake and elimination of 2',2'-difluoro-2'-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  Yusuke Nakamura,et al.  Mammalian p53R2 Protein Forms an Active Ribonucleotide Reductasein Vitro with the R1 Protein, Which Is Expressed Both in Resting Cells in Response to DNA Damage and in Proliferating Cells* , 2001, The Journal of Biological Chemistry.

[8]  C. Cass,et al.  Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells. , 2005, Biochemical pharmacology.

[9]  S. Ashley,et al.  RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine , 2004, Oncogene.

[10]  H. Niiyama,et al.  Quantitative determination of apoptotic death in cultured human pancreatic cancer cells by propidium iodide and digitonin. , 1999, Cancer letters.

[11]  J. Mackey,et al.  Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy† , 2003, Oncogene.

[12]  S. Ashley,et al.  Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer. , 2004, Surgery.

[13]  Franco Mosca,et al.  Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. , 2006, Cancer research.

[14]  B. Mitchell,et al.  Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. , 1996, Cancer research.

[15]  R. Schilsky,et al.  An investigational new drug treatment program for patients with gemcitabine , 1999, Cancer.

[16]  G. Peters,et al.  Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. , 1994, Cancer research.

[17]  L. Gelbert,et al.  An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines , 2004, Cancer Research.

[18]  Y. Takeda,et al.  Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer , 2007, International journal of cancer.

[19]  Ryuzo Ueda,et al.  Determinants of sensitivity and resistance to gemcitabine: The roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non‐small cell lung cancer , 2004, Cancer science.

[20]  Bauke Ylstra,et al.  In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. , 2005, Cancer research.